ivabradine   Click here for help

GtoPdb Ligand ID: 2357

Synonyms: Corlanor® | Corlentor® | Procoralan® | S-16257
Approved drug
ivabradine is an approved drug (EMA (2005), FDA (2015))
Compound class: Synthetic organic
Comment: Marketed drugs contain ivabradine hydrochloride (PubChem CID 3045381).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ivabradine

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 10
Topological polar surface area 60.47
Molecular weight 468.26
XLogP 2.41
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1cc2CC(c2cc1OC)CN(CCCN1CCc2c(CC1=O)cc(c(c2)OC)OC)C
Isomeric SMILES COc1cc2C[C@@H](c2cc1OC)CN(CCCN1CCc2c(CC1=O)cc(c(c2)OC)OC)C
InChI InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Across Europe, ivabradine has EMA approval for the symptomatic treatment of stable angina and chronic heart failure (HF) in patients with elevated heart rates. In August 2014 the US FDA granted priority review designation for ivabradine for the treatment of chronic HF, and in April 2015 granted approval for use of the drug in cases of worsening heart failure to reduce hospitalisation.
ivabradine has been tested for heart rate-lowering efficacy in patients with postural orthostatic tachycardia syndrome (POTS) [3]. The benefit of ivabradine over beta blockers is that it doesn't depress blood pressure, but it is not approved for treating POTS. In addition to postural orthostatic tachycardia, POTS patients also suffer from fatigue, weakness and brain fog, a set of symptoms that are experienced by 'long-COVID' patients. In view of the similar symptomology, it has been proposed that ivabradine may offer potential for managing such post-viral abnormalities in long-COVID patients.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Ivabradine inhibits the If current in the sinoatrial node (cardiac pacemaker) [2]. The heart rate is slowed down without any negative effects on myocardial contractility or ventricular repolarization.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03182725 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome Phase 3 Interventional University of California, San Diego
External links Click here for help